Drug Discovery Service
Drug discovery is conducted by filtering the compounds that can bind to known target proteins that meet the expected characteristics, and assessing their potential for conversion into drugs following executable manufacturing and effective processing. Our company provides you with professional strategies to accelerate the screening for your drug candidate, make your idea come to fruition easily and improve the probability of your candidate drug entering development in Autoimmune Diseases & Inflammation.
Drugs for Autoimmune Diseases & Inflammation
Non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids are common drugs used in the therapeutics of Autoimmune Diseases & Inflammation, characterized by their high efficacy in relieving pain and inhibiting inflammation. Additionally, disease-modifying anti-rheumatic drugs (DMARDs) have emerged as a popular therapeutics due to their clinically mildness and capacity to avoid tissue and organ damage induced by inflammatory reactions.
NSAIDs
Salicylic acid derivatives
Para-aminophenol derivatives
Fenamates
Propionic acid derivatives
Enolic acid derivatives
Diarylheterocycles...
Glucocorticoids
Prednisone
Methylprednisolone
Dexamethasone
Betamethasone...
DMARDs
Methotrexate
Leflunomide
Gold compounds
Sulfasalazine
Azathioprine
Cyclophosphamide
Cyclosporine...
Drug Targets in Autoimmune Diseases & Inflammation
As knowledge of Autoimmune Diseases & Inflammation progresses, therapeutics intending to block or inhibit the operation of receptors in certain pathways involved in inflammation have developed. As a large family of small molecules, DMARDs primarily target several classes of kinases that are essential for signaling downstream of pro-inflammatory factors, including JAKs/MAPKs/SYK-BTK/NF-κB signaling pathways, etc. Moreover, pharmacogenetics mechanisms associated with blockade of IL1, IL6 and T-cells, as well as inhibition of TNF, provide new ideas for the therapeutics of Autoimmune Diseases & Inflammation.
Fig.1 The mechanism of target synthetic DMARDs inhibition in rheumatoid arthritis (Massalska M., et al., 2020)
Our Services
Drug discovery services are aimed at assisting you speed up your identification for drugs that efficiently interact with the target proteins. Our company provides you with experienced team and necessary resources to support the small molecule drugs discovery for Autoimmune Diseases & Inflammation.
Synthesis and Production
- Synthesis of customized non-commercial compounds.
- Expression and purification of focused proteins.
Target Protein Activity Test
- Purity and concentration tests.
- Modification, stability and biological activity tests.
Structural Biology Validation
- Structure identification by X-ray crystallography, NMR and Cryo-EM.
Optimization of Target Protein Test
- Optimizations for buffer composition, enzyme concentration, reaction temperature and reaction time.
Validation Tests
- Validation for inhibitor dose titration detection, kinetic parameter optimization, target protein libraries screening.
Computational Biology
- Drug design and prediction of intermolecular interactions.
- Virtual screening.
We provide the drug discovery for Autoimmune Diseases & Inflammation including but not limited the following targets:
- Kinases: JAKs, TYK2, IRAKs, ITK, BTK, SYK, MAPKs...
- Receptors: TLRs, IL-Rs, IFNRα/β...
- Cytokines: Interleukins, IFNγ, CSF...
- Receptor-interacting protein: RIPs, BAFFR, FcεR, TLR, TNFR...
Our Advantages
One-stop services with short cycle time
Professional team with customizable studies
Timely stage reporting and whole process follow-up
High-class life science experimental equipment
Our company will escort you through all stages of drug discovery, providing you with comprehensive experience in the screening of drug candidates in autoimmune diseases & inflammation. If you are interested in our drug discovery services, please contact us for more detailed information.
Reference
- Massalska, Magdalena et al. "Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19." Cells 9,8 (2020): 1876.